Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Derek Miller, Senior Vice President of Human Resources at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $159.3 billion, recently executed significant transactions involving the company’s stock. According to a recent SEC filing, Miller sold a total of 2,024 shares of Amgen common stock over two days, amounting to approximately $593,933. The sales occurred on February 18 and February 19, 2025, with prices ranging from $292.5584 to $293.7367 per share.
Additionally, Miller exercised stock options to acquire 1,524 shares at a price of $156.35 per share on February 19, 2025. The total value of the shares acquired through this exercise was approximately $238,277. According to InvestingPro, Amgen demonstrates strong financial health with consistent dividend payments and low price volatility.
Following these transactions, Miller’s direct ownership in Amgen stands at 8,544 shares. Based on InvestingPro’s Fair Value analysis, the stock is currently trading near its Fair Value, with additional insights available in the comprehensive Pro Research Report.
In other recent news, Amgen reported a strong performance for the fourth quarter of 2024, with revenue surpassing market expectations, largely due to the success of products like Repatha, Evenity, and Tezspire. Despite a clinical hold on AMG 513, Cantor Fitzgerald maintained an Overweight rating on Amgen, though it adjusted the price target to $340, citing uncertainties surrounding the program. Erste Group upgraded Amgen’s stock rating to Buy, highlighting the company’s strong financial margins and attractive valuation compared to sector averages. Piper Sandler raised its price target for Amgen to $329, maintaining an Overweight rating, and expressed optimism about Tezspire’s potential as a significant revenue driver. Meanwhile, RBC Capital slightly reduced its price target to $320 but retained an Outperform rating, acknowledging Amgen’s solid core business and future growth prospects. Bernstein also adjusted its price target to $350 while maintaining an Outperform rating, noting the potential challenges but remaining positive about Amgen’s diverse growth opportunities. These recent developments reflect a mix of cautious optimism and strategic adjustments by analysts in response to Amgen’s current and future endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.